Bristol Myers Squibb’s Zeposia (ozanimod) won approval from the U.S. Food and Drug Administration as a new treatment for a type of multiple sclerosis.

In a second research report published this year so far, investigators found that the U.S. Food and Drug Administration (FDA) is approving drugs faster than ever.

Changes in U.S. Food and Drug Administration procedures meant to speed approvals for medications may have resulted in less exacting standards, a new analysis suggests.